

GSK delivers FY 2021 sales of £34 billion +5%



Continued momentum in R&D delivery and strengthening of pipeline



Emma Walmsley
CEO, GSK

Pharma
£17.7bn
+ 10%

Vaccines
£6.8bn
+ 2%

Consumer
£9.6bn
+ 4%*



87.6p
- 13%

Total EPS

113.2p
+ 9%

Adjusted EPS

£4.4bn

Free cash flow

80p

Dividend

3

major product approvals
in 2021

Strong pipeline of

21 **43**

Vaccines

Medicines

“We have ended the year strongly, with another quarter of excellent performance driven by first-class commercial execution, and we enter 2022 with good momentum. This is going to be a landmark year for GSK, with a step-change in growth expected and multiple R&D catalysts, including milestones on up to 7 key late-stage pipeline assets. 2022 is also the year when we demerge our world-leading Consumer Healthcare business. At our capital markets event later this month, we will set out the future growth ambitions and highly attractive financial profile of this business, and the outstanding opportunity it provides for shareholders.”

All % at constant exchange rates (CER)

Journalists/media see press release on www.gsk.com for full details on FY/Q4 2021.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 62 and 63 of the press release.

*Excluding brands divested/under review